BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX) announced positive results for the Phase IIa clinical trial of BL-7040, an oral treatment for inflammatory bowel disease (IBD). The study found that BL-7040 is safe and effective in treating ulcerative colitis, a form of IBD. The drug was also well tolerated by the study participants, with only mild to moderate adverse events.
In the study at five Israeli hospitals, patients with moderately active ulcerative colitis were treated with varying dosages of BL-7040 over five weeks, followed by a two-week follow-up. 16 of the 22 patients enrolled completed the study. Half the patients achieved the primary endpoint – a reduction in the Mayo score between baseline and completion of treatment and the